Furthermore, pathways regulated by APP, L1CAM, and genes from the caspase family may represent promising therapeutic targets of miRNAs in AD and PD, being therapeutic targets of deregulated miRNAs in both disorders [72]. This evidence concerns the gene L1CAM and Parkinson disease.